Trial Profile

An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olezarsen (Primary)
Indications Hypertriglyceridaemia
Focus Adverse reactions; Registrational
Sponsors Ionis Pharmaceuticals

Most Recent Events

27 Apr 2025 Planned End Date changed from 1 Sep 2026 to 1 Mar 2027.
27 Apr 2025 Planned primary completion date changed from 1 May 2026 to 1 Mar 2027.
26 Mar 2025 According to an Ionis Pharmaceuticals media release, the company anticipate data from robust sHTG Phase 3 program in 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com